1Monti G, Herrera M, Kindge-Milles D, et al. The dose response multicenter international collaborative initiative (DO-RE-MI) [ J]. Contrib Nephrol, 2007, 156(2) : 434-443.
2Ronco C, Bellomo R, Homel P, et al. Effects of different doses in continuous veno-venous hemofiltration on outcomes of acute renal failure: a prospective randomized trial [ J ]. Lancet, 2000, 356 (9223) : 26-30.
3Tan HK, Baldwin I, Bellomo R. Continuous venovenous hemofil- tration without anticoagu- lation in high-risk patients[ J]. Intensive Care Med, 2000,26(11) :1652-1657.
4Nagarik AP, Soni SS, Adikey GK, et al. Comparative study of an- ticoagulation versus saline flushes in continuous renal replacement therapy[ J]. Saudi J Kidney Dis Transpl, 2010,21 (3) :478-483.
5Ramesh Frasad GV, Palevsky PM, Burr R, et al. Factors affecting system clotting in continuous renal replacement therapy: results of a randomized, controlled trial [ J ]. Clin Nephrol, 2000, 53 ( 1 ) : 55 -60.
6Sagedal S, Hartmann A, Osnes K, et al. Intermittent saline flushes dtlring haemodialysis do not alleviate coagulation and clot formation in stable patients receiving reduced doses of daheparin [ J ]. Nephrol Dial Transplant, 2006,21 ( 2 ) : 444-449.
7Khwaja A. KDIGO clinical practice guideline for acute kidney injury[ J]. Nephron Clin Pract,2012,120(4) : 179-184.
